Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01223586
Other study ID # H22-42
Secondary ID
Status Completed
Phase N/A
First received October 18, 2010
Last updated April 21, 2012
Start date November 2010
Est. completion date May 2011

Study information

Verified date April 2012
Source Kyoto University
Contact n/a
Is FDA regulated No
Health authority Japan: Ministry of Health, Labor and Welfare
Study type Observational

Clinical Trial Summary

The objective of this study is to verify the relationship between coronary plaque regression and cardiovascular prevention in long term follow up of the Japan Assessment of Pitavastatin and Atorvastatin in Acute Coronary Syndrome (JAPAN-ACS) study [NCT00242944]. In addition, the effect of serum lipid levels or different type of statins on cardiovascular prevention will also be examined.


Description:

Several previous multicenter studies using intravascular ultrasound (IVUS) imaging have revealed that statins attenuate the progression of atherosclerosis or even provide regression of plaque volume. Indeed, the Japan Assessment of Pitavastatin and Atorvastatin in Acute Coronary Syndrome (JAPAN-ACS) trial [NCT00242944] has revealed that early aggressive statin therapy in patients with acute coronary syndrome (ACS) significantly reduces the plaque volume of non-culprit coronary lesions On the other hands, a direct relationship between atheroma progression and regression on IVUS and clinical events has not been clearly defined. To verify that relationship, long term follow up of the JAPAN-ACS study will be performed. Clinical outcome of patients with regressed plaque and progressed plaque will be compared. In addition, the objectives of this study are to evaluate the effect of serum lipid levels or different type of statins on cardiovascular prevention.


Recruitment information / eligibility

Status Completed
Enrollment 238
Est. completion date May 2011
Est. primary completion date May 2011
Accepts healthy volunteers No
Gender Both
Age group 20 Years and older
Eligibility At the enrollment of original study

Inclusion Criteria:

- Patients with written consent by their own volition after being provided sufficient explanation for their participation in this clinical trial

- Patients 20 years or older at the time of their consent

- Patients with hypercholesterolemia as defined by any of the following criteria:

TC >= 220 mg/dL; LDL-C >= 140 mg/dL; Cholesterol-lowering treatment is necessary in accordance with the investigator's judgement when LDL-C >= 100 mg/dL or TC >= 180 mg/dL.

- Patients who have been diagnosed with acute coronary syndrome

- Patients with successful percutaneous coronary intervention (PCI) by intravascular ultrasound (IVUS) guidance

- Patients having coronary plaques (>= 500 µm in thickness or 20% or more in % plaque) at >= 5 mm from the previously treated area in the same branch of coronary artery

Exclusion Criteria:

- Patients with bypass graft or in-stent restenosis at the site of PCI

- Patients who had received PCI on the lesion in the past where the evaluation of coronary plaque volume is planned

- Patients who had plaques in a non-culprit site and might receive PCI during the treatment period

- Patients receiving lipid-lowering drugs (statins, fibrates, probucol, nicotinic acid or cholesterol absorption inhibitors)

- Patients with familial hypercholesterolemia

- Patients with cardiogenic shock

- Patients receiving cyclosporine

- Patients with any allergy to pitavastatin or atorvastatin

- Patients with hepatobiliary disorders

- Pregnant women, women suspected of being pregnant, or lactating women

- Patients with renal disorders or undergoing dialysis

- Patients who are ineligible in the opinion of the investigator

Study Design

Observational Model: Cohort, Time Perspective: Retrospective


Locations

Country Name City State
Japan Division of Cardiology, Kyoto University Hospital Kyoto
Japan Division of Cardiology, Department of Medicine and Clinical Science, Yamaguchi University Graduate School of Medicine Ube Yamaguchi

Sponsors (2)

Lead Sponsor Collaborator
Kyoto University Yamaguchi University Hospital

Country where clinical trial is conducted

Japan, 

References & Publications (1)

Miyauchi K, Daida H, Morimoto T, Hiro T, Kimura T, Nakagawa Y, Yamagishi M, Ozaki Y, Kadota K, Kimura K, Hirayama A, Kimura K, Hasegawa Y, Uchiyama S, Matsuzaki M; JAPAN-ACS Investigators. Reverse vessel remodeling but not coronary plaque regression could — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Composite endpoint Occurrence of one of following events:
Cardiovascular death (death from cardiac cause or stroke or peripheral artery disease) Non-fatal Myocardial Infarction (MI) Non-fatal Cerebral Infarction (CI) except for transient ischemic attack (TIA) Unstable angina requiring urgent hospitalizations
4-year Yes
Secondary Composite cardiovascular events Occurrence of one of following events:
Cardiovascular death Non-fatal MI Non-fatal CI Unstable angina requiring hospitalizations Ischemia-driven coronary revascularization except target lesion revascularization (TLR)
4-year Yes
Secondary Composite coronary heart disease events Occurrence of one of following events:
Coronary heart disease (CHD) death Non-fatal MI Unstable angina requiring urgent hospitalizations Ischemia-driven coronary revascularization except TLR
4-year Yes
Secondary Composite cerebrovascular events Occurrence of one of following events:
Fatal and Non-fatal stroke Transient ischemic attack requiring hospitalizations
4-year Yes
Secondary Mortality Occurrence of each following events:
All-cause mortality Cardiovascular death Cardiac death (death from coronary disease or heart failure or arrhythmia and sudden death) CHD death (death from myocardial infarction and sudden death)
4-year Yes
Secondary Heart disease events Occurrence of each following events:
Fatal and Non-fatal MI Non-procedure related MI Procedure related MI Unstable angina requiring urgent hospitalizations Resuscitated cardiac arrest Hospitalization for heart failure PCI or CABG
All events of PCI or CABG
TLR
non-TLR
Ischemia-driven PCI or CABG
TLR
non-TLR
4-year Yes
Secondary Cerebrovascular events Occurrence of each following events:
Fatal and Non-fatal stroke Fatal and Non-fatal CI
Non-procedure related CI
Procedure related CI Fatal and Non-fatal cerebral hemorrhage Hospitalization for TIA
4-year Yes
Secondary Other events Occurrence of each following events:
Operation for or rupture of aortic aneurysm Revascularization for peripheral arterial disease (PAD) Carotid artery stenting (CAS) or carotid endarterectomy (CEA) Aortic dissection Deep vein thrombosis (DVT) or pulmonary thromboembolism (PTE) New occurrence of malignant tumor Operation for aortic stenosis
4-year Yes
See also
  Status Clinical Trial Phase
Recruiting NCT05846893 - Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease N/A
Recruiting NCT06013813 - Conventional vs. Distal Radial Access Outcomes in STEMI Patients Treated by PCI N/A
Recruiting NCT05412927 - AngelMed Guardian® System PMA Post Approval Study
Completed NCT02750579 - Early or Delayed Revascularization for Intermediate and High-risk Non ST-elevation Acute Coronary Syndromes? N/A
Completed NCT04102410 - Assessing Force-velocity Profile: an Innovative Approach to Optimize Cardiac Rehabilitation in Coronary Patients N/A
Enrolling by invitation NCT03342131 - Serum Concentration of Wnt2 and Wnt4 in Patients With Acute Coronary Syndrome N/A
Recruiting NCT01218776 - International Survey of Acute Coronary Syndromes in Transitional Countries
Enrolling by invitation NCT04676100 - International CR Registry
Completed NCT03590535 - 5th Generation cTnT in ED ACS
Recruiting NCT05437900 - INSIGHTFUL-FFR Clinical Trial Phase 4
Completed NCT05551429 - Factors Related to Participation in Cardiac Rehabilitation in Patients With Acute Coronary Syndrome
Terminated NCT04316481 - IDE-ALERTS Continued Access Study N/A
Active, not recruiting NCT04475380 - Complex All-comers and Patients With Diabetes or Prediabetes, Treated With Xience Sierra Everolimus-eluting Stents
Not yet recruiting NCT04852146 - Electronic Feedback for Data Restitution and Valorization to the Emergency Teams in Aquitaine.
Active, not recruiting NCT02892903 - In the Management of Coronary Artery Disease, Does Routine Pressure Wire Assessment at the Time of Coronary Angiography Affect Management Strategy, Hospital Costs and Outcomes? N/A
Completed NCT02944123 - Half Dose of Prasugrel and Ticagrelor in Acute Coronary Syndrome (HOPE-TAILOR) Phase 3
Completed NCT04077229 - Piloting Text Messages to Promote Positive Affect and Physical Activity N/A
Not yet recruiting NCT02871622 - BMX Alpha Registry: a Post-market Registry of the BioMatrix Alpha TM N/A
Active, not recruiting NCT02922140 - The Impact of Pharmaceutical Care Practice on Patients in Cardiac Rehabilitation Unit N/A
Completed NCT02673437 - Rivaroxaban ACS Specialist Cohort Event Monitoring Study